Peregrine Pharmaceuticals (NASDAQ:PPHM) will report second quarter results after the bell today, and given that shares have done little this year, investors are right to be looking for clues as to when the company's promising immunotherapy drug for cancer may make an impact.

PPHM Chart

PPHM data by YCharts

In the following slideshow, I offer insight into Peregrine's bavituximab and outline key questions I'll be looking to have answered during the second quarter conference call.